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Advanced Breast Cancer (ABC) is a treatable but still generally
incurable disease. The goals of care are to optimize both length and
quality of life. Due to continuous research, several advances have
beenmade, particularly for the HER-2-positive and for Luminal-like
subtypes. Notwithstanding these advances, median overall survival
of patients with ABC is still only 2e3 years, although the range is
wide [1e5], and survival may be longer for patients treated in
specialized institutions [6]. Implementation of current knowledge
is highly variable among countries and within each country.
The use of treatment guidelines has been associated with a
significant improvement in survival [7e9]. This has been achieved
mainly in early breast cancer. For ABC, and particularly metastatic
breast cancer (MBC), less level 1 evidence exists and only recently
have international consensus guidelines been developed (ABC1 e
[10]. The ABC Consensus Conference was created by the European
School of Oncology (ESO) with the ambitious goal of improving
outcomes for all patients with advanced breast cancer. Backed by
strong political advocacy, ABC guidelines are seeking to improve
standards of care, to raise awareness about how to best meet to the
needs of this underserved group of patients, and to identify
research priorities so that clinical research is focused on the most
important areas of unmet need.
Following the work of the ESO-ABC Task Force [11e14], created
in 2005, and the successful undertaking of the 1st International
Consensus Guidelines Conference on ABC (ABC1), held in
November 2011, the 2nd International Consensus Conference for
Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, onTable 1
Levels of evidence grading system [15].
Grade of recommendation/
description
Benefit vs. risk and burdens Methodolog
1 A/Strong recommendation,
high quality evidence
Benefits clearly outweigh risk






Benefits clearly outweigh risk







Benefits clearly outweigh risk



















Benefits closely balanced with
risks and burden
ObservationNovember 7e9, 2013. The conference brought together about 1100
participants from 71 countries, including health professionals, pa-
tient advocates and journalists. A series of guidelines were dis-
cussed and agreed upon, based on the most up-to-date evidence
and can be used to guide treatment decision-making in diverse
health care settings globally. These guidelines are developed as a
joint effort from ESO and ESMO (European Society of Medical
Oncology), are endorsed by EUSOMA (European Society of Breast
Cancer Specialists), SIS (Senologic International Society) and Flam
(Federacion Latino Americana de Mastologia), and organized under
the auspices of UICC (Union Internationale Contre Le Cancer), OECI
(Organization of European Cancer Institutes) and the BCRF (Breast
Cancer Research Foundation).
The present manuscript summarizes the guidelines developed
at ABC2. The guidelines include the level of evidence, the per-
centage of panel members who agreed with the consensus state-
ments, and the supporting references for each recommendation.
Importantly, the ABC guidelines are developed as clinical man-
agement recommendations potentially applicable worldwide,
albeit with the necessary adjustments for each country, depending
on access to therapies. The guidelines are based on the underlying
principles of modern oncology, emphasizing the crucial role of a
multidisciplinary and individualized approach that respects the
specificities of the advanced setting and the preferences of each
patient. The manuscript also clearly highlights areas where
research efforts are urgently needed.Methodology
Prior to the ABC2 Conference, a set of preliminary recommen-
dation statements on the treatment of ABC were prepared, based
on available published data and following the ESMO guidelines
methodology. These recommendations were circulated to all 43
panel members by email for comments and corrections on content
and wording. A final set of recommendations was presented, dis-
cussed and voted upon during the consensus session of ABC2. Allical quality of supporting evidence Implications
ut important limitations or
ing evidence from observational
Strong recommendation, can apply to
most patients in most circumstances
without reservation
mportant limitations (inconsistent
thodological flaws, indirect, or
or exceptionally strong evidence
vational studies
Strong recommendation, can apply to
most patients in most circumstances
without reservation
al studies or case series Strong recommendation, but may
change when higher quality evidence
becomes available
ut important limitations or
ing evidence from observational
Weak recommendation, best action
may differ depending on circumstances
or patients' or societal values
mportant limitations (inconsistent
thodological flaws, indirect, or
or exceptionally strong evidence
vational studies
Weak recommendation, best action
may differ depending on circumstances
or patients' or societal values
al studies or case series Very weak recommendation, other
alternatives may be equally reasonable
F. Cardoso et al. / The Breast 23 (2014) 489e502 491panel members were instructed to vote on all questions, with
members with a potential conflict of interest or who did not feel
comfortable answering the question (e.g. because it is not their area
of expertise) instructed to “abstain” from voting. Additional
changes in the wording of statements were made during the ses-
sion. The statement on Everolimus was updated after the presen-
tation of the overall survival results of the BOLERO-2 trial and re-
voted by email by all panel members.
Supplementary Table 1 lists all members of the ABC2 consensus
panel and their disclosure of any relationships that could be
perceived as a potential conflict of interest.
Table 1 describes the grading system used [15].
Three main issues were discussed at ABC2: inoperable locally
advanced breast cancer (LABC) both inflammatory and nonin-
flammatory; MBC; and specific definitions for which a consensus
was deemed important.
For clarification, ABC comprises both inoperable LABC and MBC
or stage IV. Some of the ABC guidelines apply to both LABC and
MBC, while others are specific to each of the settings.
General guidelinesGuideline statement LoE Consensus
All ABC patients should be offered
comprehensive, culturally sensitive, up-to-
date and easy to understand information
about their disease and its management.
I B 97.2% (36) Yes
0% (0) Abstain
(37 voters)
Specialized oncology nurses (if possible
specialized breast nurses) should be part of
the multidisciplinary team managing ABC
pts. In some countries, this role may be
played by a physician assistant or other







Strong consideration should be given to the use
of validated instruments for patients to
report the symptoms of disease and side
effects of treatment they experience as a
regular part of their clinical care. These PRO
(patient-reported outcomes) instruments
should be simple and user-friendly to
facilitate their use in clinical practice. This
systematic monitoring will serve to facilitate
communication between patients and their
treatment teams, allow optimal quality of
life, and may better characterize the
toxicities of all anticancer therapies.
I C 89.4% (34) Yes
5.2% (2) Abstain
(38 voters)
The age of the patient should not be the sole
reason to withhold effective therapy (in
elderly patients) nor to overtreat (in young
patients). Age alone should not determine
the type and intensity of treatment.
I B 100% (38) Yes
0% (0) Abstain
(38 voters)
LoE: Available level of evidence; Consensus: Percentage of panel members in
agreement with the statement.ABC1 Guidelines had already emphasised the importance of
including the patient in all steps of the decision-making process
[10]. For active and informed participation, patients must have
access to comprehensive, culturally sensitive, up-to-date and easy
to understand information about their disease and its
management.
A “patient navigator” can help the patient going through all
phases of the cancer journey [16e20]. This is particularly relevant
for advanced cancer patients who are often overwhelmed with
difficult decisions to make, through complex information and
available treatment options, and are frequently co-managed by the
breast cancer and the palliative care teams. This role is best taken
by a specialized breast nurse, or at least a specialized oncologynurse, who should be part of the multidisciplinary team managing
ABC patients. In some countries however, this role may be played
by a physician assistant or another trained and specialized health
care practitioner. It is also recognized that in many centres it is not
yet possible for each patient to have a navigator due to lack of
human resources.
There is an implicit assumption that the recording of adverse
events by clinicians reliably documents patients' side effects and
symptoms. However, there is an accumulating body of evidence
suggesting that the frequency and severity of many symptoms that
impact upon an individual patient's quality of life go under-reported,
under-recognised and consequently under-treated [21]. Since qual-
ity of life is one of the main aims of ABC treatment, this poses an
important problem. It is also potentially dangerous from a drug
safety point of view. The inability of traditional methods for
capturing adverse events has led to renewed interest in incorpo-
rating Patient Reported Outcomes (PROs/PROMs) with Common
Terminology Criteria for Adverse Events (CTC-AEs) in clinical trials,
as well as utilising PROs outside a clinical trial setting to reflect and
monitor more accurately the harms and benefits of patient experi-
ence. This may be particularly important for drugs approved based
solely on progression-free survival (PFS) benefits or only modest
overall survival (OS) benefits, for which the balance between efficacy
and toxicity may be more difficult to accurately determine. Many
standardised, well-validated instruments or PRO measures are
available with translations into most languages. The most frequently
used are the generic EORTC-QLQ-C3 (http://groups.eortc.be/qol/
eortc-qlq-c30) and the FACT (http://www.facit.org/FACITOrg/
Questionnaires). Both have breast cancer specific modules/sub-
scales (EORTC QLQ-BR23 and FACT-B) and the FACT in particular has
several other specific subscales covering, for example, treatment
with EGFR inhibitors, taxanes, anti-angiogenesis drugs, endocrine
agents and monoclonal antibodies. Recently the FDA and EMA have
published guidance for industry on how to utilise PROs in applica-
tions for drug labelling claims. There has also been an important
initiative, funded by the NCI, to produce a Patient-Reported Out-
comes version of the Common Terminology Criteria for Adverse
Events (PRO-CTCAE), which is suggested for use in NCI sponsored
trials (http://outcomes.cancer.gov/tools/pro-ctcae.html).
Although age is an important factor to consider in decision-
making for ABC, it must not be the sole factor to determine the in-
tensity and type of treatment. There is a tendency to withhold
therapy in some elderly patients because of fear of toxicity or
concern about co-morbidity. In some cases, however, such therapies
may be highly effective and could improve both survival and quality
of life. At the same time, younger patients are often overtreated or
treated somewhat inappropriately. Age may influence breast cancer
treatment, but it should not be the guiding force [10,22e24].
“Survivorship” in ABC
The complex needs of patients living with ABC, at times for
many years, as well as their caregivers, should be addressed not
only in terms of supportive and palliative care but also regarding
“survivorship” concerns. The multidisciplinary approach of ABC
should encompass early in the history of the disease not only
physical but also functional, social, psychological and spiritual do-
mains [25e27].
It is important to clearly define the disease context with patients
and families, addressing the concept of uncertainty and tailoring
the treatment strategy according to individual priorities and dis-
ease status [28]. Specific psychosocial needs of young and elderly
patients should also be recognized and supported, i.e. social secu-
rity, job flexibility, rehabilitation, body image (including sexuality),
home and child care.
(continued )
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VISCERAL CRISIS is defined as severe organ
dysfunction as assessed by signs and
symptoms, laboratory studies, and rapid
progression of disease. Visceral crisis is not
the mere presence of visceral metastases, but
implies important visceral compromise
leading to a clinical indication for a more
rapidly efficacious therapy, particularly since
another treatment option at progression will







PRIMARY ENDOCRINE RESISTANCE is defined
as: relapse while on the first 2 years of
adjuvant ET, or PD within first 6 months of
1st line ET for MBC, while on ET
SECONDARY (ACQUIRED) ENDOCRINE
RESISTANCE is defined as: relapse while on
adjuvant ET but after the first 2 years, or
relapse within 12 months of completing
adjuvant ET, or PD 6months after initiating







LoE: Available level of evidence; Consensus: Percentage of panel members in
agreement with the statement; ET: endocrine therapy; PD: progressive disease;
MBC: metastatic breast cancer.
Guideline statement LoE Consensus
A combined treatment modality based on a
multidisciplinary approach (systemic
therapy, surgery and radiotherapy) is





For TRIPLE NEGATIVE LABC, anthracycline- and-
taxane-based chemotherapy is
recommended as initial treatment.
I A 85.3% (35) Yes
9.7% (4) Abstain
(41 voters)
For HER-2-POSITIVE LABC, concurrent taxane
and anti-HER-2 therapy is recommended
since it increases the rate of pathological
complete response (pCR).
I A 91.8% (34) Yes
5.4% (2) Abstain
(37 voters)
For HER-2-POSITIVE LABC, anthracycline-based
chemotherapy should be incorporated in the
treatment regimen.
I A 71.7% (28) Yes
12.8% (5) Abstain
(39 voters)
In HER-2-POSITIVE LABC, when an
anthracycline is given, it should be
administered sequentially with the anti-
HER-2 therapy.
I A 86.8% (33) Yes
10.5% (4) Abstain
(38 voters)
Options for HORMONAL RECEPTOR POSITIVE
LABC include an anthracycline- and taxane-
based chemotherapy regimen, or endocrine
therapy.
The choice of chemotherapy vs. endocrine
therapy, as initial treatment, will depend on
tumour (grade, biomarker expression) and
patient (menopausal status, performance
status, comorbidities, preference)
considerations.
I A 85.3% (35) Yes
9.7% (4) Abstain
(41 voters)
Following effective neoadjuvant systemic
therapy with or without radiotherapy,
surgery will be possible in many patients.
This will consist of mastectomy with axillary
dissection in the vast majority of cases, but in
selected patients with a good response,
breast conserving surgery may be possible.
II B 97.5% (39) Yes
0% Abstain
(40 voters)
LABC: locally advanced breast cancer; LoE: Available level of evidence; Consensus:
Percentage of panel members in agreement with the statement; ER: oestrogen re-
ceptor; PR: progesterone receptor.Current terminology uses several ill-defined terms that often have
different meanings, leading to confusion and difficulty in adapting
clinical trial findings to current practice populations.
The ABC2 Panel tried to define two of these important terms,
aiming at standardization of their use.
Regarding endocrine resistance, an attempt was made to be
consistent with a definition reached by a number of investigators
involved in breast cancer clinical trials, at a meeting sponsored by
NCI held in May 2012 and later approved by the North American
Breast Cancer Groups (NABCG).
It is also important to note that endocrine resistance is a con-
tinuum and that strict definitions are mainly helpful for the clinical
trials setting and not necessarily for routine clinical practice.Guideline statement LoE Consensus
For inflammatory LABC, overall treatment I B 92.6% (38) YesInoperable locally advanced, non-inflammatory, breast cancerGuideline statement LoE Consensus
Before starting any therapy, a core biopsy
providing histology and biomarker (ER, PR,
HER-2, proliferation/grade) expression is
indispensable to guide treatment decisions.
I B 97.2% (36) Yes
2.7% (1) Abstain
(37 voters)
Since LABC patients have a significant risk of
metastatic disease, a full staging workup,
including a complete history, physical
examination, lab tests and imaging of chest
and abdomen (preferably CT scans) and bone,
prior to initiation of systemic therapy is
highly recommended.
I B 100% (37) Yes
0% (0) Abstain
(37 voters)
PET-CT, if available, may be used (instead of and
not on top of CT scans and bone scan).
II B 100% (37) Yes
0% (0) Abstain
(37 voters)
Systemic therapy (not surgery or radiotherapy)
should be the initial treatment. If LABC
remains inoperable after systemic therapy
and eventual radiation, “palliative”
mastectomy should not be done, unless the
surgery is likely to result in an overall






I AInoperable locally advanced, inflammatory, breast cancerrecommendations are similar to those for
non-inflammatory LABC, with systemic
therapy as first treatment.
4.8% (2) Abstain
(41 voters)
Mastectomy with axillary dissection is
recommended in almost all cases, even when
there is good response to primary systemic
therapy.
I B 95.1% (39) Yes
4.8% (2) Abstain
(41 voters)
Immediate reconstruction is generally not







Loco-regional radiotherapy (chest wall and
lymph nodes) is required, even when a pCR is
achieved with systemic therapy.
I B 97.5% (39) Yes
2.5% (1) Abstain
(40 voters)
MBC: metastatic breast cancer; LoE: Available level of evidence; Consensus: Per-
centage of panel members in agreement with the statement; pCR: pathological
complete remission.LABC occurs at first presentation in about one fifth of breast
cancer patients worldwide, with lower incidence in countries with
established screening programs but as high as 60% in some other
countries [29]. Usually, the definition of LABC includes large oper-
able primary breast tumours (stage IIB, IIIA) and/or those involving
(continued )
Guideline statement LoE Consensus
For MALE PATIENTS WITH ABC who need to
receive an aromatase inhibitor, a
concomitant LHRH agonist or orchiectomy is
the preferred option. Aromatase inhibitor
monotherapy may also be considered, with
close monitoring of response.







MBC: metastatic breast cancer; LoE: Available level of evidence; Consensus: Per-
centage of panel members in agreement with the statement.
F. Cardoso et al. / The Breast 23 (2014) 489e502 493the skin or chest wall and/or those with extensive lymphadenop-
athies (stage IIIB, IIIC) [30]. For the purpose of ABC guidelines we
define LABC as inoperable locally advanced disease that has not yet
spread to distant sites.
Inoperable LABC is a heterogeneous designation encompassing
a range of clinical situations from neglected low-grade ER-positive
breast cancers to rapidly progressing usually ER-negative disease
[30e33].
A more homogenous form of LABC is inflammatory breast can-
cer (IBC), a distinct clinic-pathologic entity. IBC has a greater as-
sociation with younger age at diagnosis, higher tumour grade, and
negative oestrogen receptor (ER) status.
The first steps in the management of this disease are a core
biopsy to provide histology and biomarker assessment
(including ER, PR, HER-2, proliferation/grade), and a full staging
workup. Due to a relatively high risk of distant metastases [34],
thoracic and abdominal CT scans are preferred to thorax X-ray
and liver ultrasound, and a PET-CT is also an acceptable option
[34].
A multimodality approach is key for loco-regional control and
survival, including systemic therapies, surgery and radiation.
The type of systemic therapy is similar to the one used in the
(neo)adjuvant setting, with anthracycline and taxanes as the
backbone of the chemotherapy regimes. For HER-2-positive LABC,
anthracyclines should not be administered concurrently with
trastuzumab since this approach does not increase the pCR rate,
and it could increase the risk of cardiac toxicity, based largely on
studies in the metastatic setting [35,36].
For luminal-like LABC, initial treatment options include
chemotherapy (with sequential anthracyclines and taxanes) and
endocrine therapy, depending on tumour (grade, biomarker
expression) and patient characteristics (menopausal status,
performance status, comorbidities) and preferences. A number
of studies have demonstrated significant activity of endocrine
therapy, particularly in luminal A-like disease [37e40]. Data
presented after ABC2 strongly suggest that this subset of breast
cancer, especially lobular histology, is less sensitive to chemo-
therapy (at least in terms of pCR rate) [41]. Very few data exist
on primary endocrine therapy in premenopausal women [42]
and, therefore, it cannot be recommended outside of clinical
trials.
Primary systemic therapy in inoperable LABC allows breast
conserving surgery in variable percentages depending on tumour/
patient characteristics [43]. Mastectomy remains the only option
before or after radiotherapy for those patients not amenable to
breast conservation and for all patients with IBC [44]. For the time
being, axillary dissection is still standard of care in inoperable LABC
[45].
As for all other stages of breast cancer, decision-making at a
multidisciplinary tumour board is highly recommended.
Specific ABC populationsGuideline statement LoE Consensus
In patients with BRCAeASSOCIATED TRIPLE
NEGATIVE OR ENDOCRINEeRESISTANT
MBC previously treated with an
anthracycline and a taxane (in the adjuvant
or metastatic setting), a platinum regimen
may be considered, if the patient is not
included in a clinical trial.
All other treatment recommendations are
similar to sporadic MBC.
I C 82.5% (33) Yes
12.5% (5) Abstain
(40 voters)As predicted by their DNA-damaging mechanism of action,
platinum compounds are expected to be particularly active in tu-
mours deficient of mechanisms responsible for DNA damage repair,
e.g. those without active BRCA1/2 proteins. Due to rarity of such
patients, little evidence exists on the clinical activity of these drugs
in BRCA1/2 mutation carriers in the metastatic setting. However,
available data suggest their promising activity mostly in the neo-
adjuvant setting [46,47], and to a lesser degree in advanced disease
[48].
In triple-negative breast cancer (TNBC), another putatively
BRCA-deficient population, a relatively large amount of data
from prospective studies, recently summarized in a meta-
analysis, demonstrated improved pCR rates in patients whose
neoadjuvant treatment included a platinum compound
[49e51]. However, which patients definitely benefit is not yet
clear since there is also one negative GEICAM study adding
carboplatin to EC-Docetaxel in basal-like breast cancer [52].
Fewer data exist for inclusion of platinum in the treatment of
metastatic disease, although the benefit in the TNBC popula-
tion seems to be larger than in other breast cancer patients
[53].
Taking available evidence into account, most of the ABC2
panel supported the inclusion of platinum-containing regimens
in the treatment of BRCA1/2 mutant patients pretreated with
anthracyclines and taxanes and demonstrated to be endocrine-
resistant.
ABC1 issued several recommendations for the treatment of
male patients with ABC [10] that still remain valid for ABC2 (see
Table 2). One additional recommendation is added at this point,
related to the use of aromatase inhibitors in this patient
population.
There are concerns about the efficacy of these agents when used
in monotherapy in male patients, due to the hypothalamic-
pituitary negative feedback.
Important differences exist in the physiology of oestrogen
production between men and women. In men, 80% of circu-
lating oestrogens result from the peripheral aromatization of
androgens, whereas 20% are directly secreted in the testicles
[54e56]. Adrenals secrete less than 1% of circulating sex ste-
roids, but precursors can undergo peripheral aromatization. So
peripheral conversion results in less than 5% of all testos-
terone, 80% of all dihydrotestosterone and oestradiol, and
nearly all of estrone (98%) [56,57]. Additionally, oestradiol
levels are 3e4 times higher in older males than in post-
menopausal females.
For these reasons, and despite the lack of prospective and ran-
domized data, the majority of panel members recommend that
when an aromatase inhibitor needs to be used in male ABC pa-
tients, a concomitant LHRH agonist or orchiectomy should be added
to further down-regulate testicular function.
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Prospective randomized clinical trials of local
therapy for breast cancer LIVER
METASTASES are urgently needed, since
available evidence comes only from series
in highly selected patients. Since there are
no randomized data supporting the effect
of local therapy on survival, every patient
must be informed of this when discussing a
potential local therapy technique. Local
therapy should only be proposed in very
selected cases of good performance status,
with limited liver involvement, no extra-
hepatic lesions, after adequate systemic
therapy has demonstrated control of the
disease. Currently, there are no data to
select the best technique for the individual
patient (surgery, stereotactic RT, intra-






MALIGNANT PLEURAL EFFUSIONS require
systemic treatment with/without local
management. Thoracentesis for diagnosis
should be performed if it is likely that this
will change clinical management. False
negative results are common. Drainage is
recommended in patients with
symptomatic, clinically significant pleural
effusion. Use of an intrapleural catheter or
intrapleural administration of talc or drugs
(e.g. bleomycin, biological response
modifiers) can be helpful.
Clinical trials evaluating the best technique
are needed.
II B 86.4% (32) Yes
10.8% (4) Abstain
(37 voters)
Chest wall and regional (nodal) recurrences
Due to the high risk of concomitant distant
metastases, patients with chest wall or
regional (nodal) recurrence should
undergo full restaging, including






Chest wall and regional recurrences should be
treated with surgical excision when
feasible with limited risk of morbidity.
I B 97.3% (37) Yes
2.6% (1) Abstain
(38 voters)
Locoregional radiotherapy is indicated for
patients not previously irradiated.
I B 97.3% (37) Yes
2.6% (1) Abstain
(38 voters)
For patients previously irradiated, re-
irradiation of all or part of the chest wall






In addition to local therapy (surgery and/or
RT), in the absence of distant metastases,
the use of systemic therapy (CT, ET and/or
anti-HER-2 therapy) should be considered.
CT after first local or regional recurrence
improves long-term outcomes primarily in
ER negative disease.
ET in this setting improves long-term
outcomes for ER positive disease.
The choice of systemic treatment depends on
tumour biology, previous treatments,
length of disease free interval, and patient-
related factors (co-morbidities,
preferences, etc).
I B 94.8% (37) Yes
5.1% (2) Abstain
(39 voters)
In patients with disease not amenable to
radical local treatment, the choice of
palliative systemic therapy should bemade
according to principles previously defined
for metastatic BC. These patients may still






MBC: metastatic breast cancer; LoE: Available level of evidence; Consensus: Per-
centage of panel members in agreement with the statement; CT: chemotherapy; RT:
radiotherapy; ET: endocrine therapy.Due to the lack of prospective randomized data for the man-
agement of liver metastases from breast cancer, and the existence
of several loco-regional techniques, local therapy of liver metasta-
ses should only be considered in highly selected patients. Each case
should be discussed with a multidisciplinary tumour board, before
a decision is made. Inclusion in a clinical trial, when available, is
considered the best option.
When breast cancer recurs only on the chest wall after mastec-
tomy, the use of intensive local-regional therapy should be consid-
ered. Therapy can include surgical excision alone, surgical excision
followed by radiation therapy, radiation therapy alone (when sur-
gical excision is not feasible) or concurrent chemotherapy and ra-
diation. Complete surgical resection reduces the total required dose
of radiation therapy and also maximizes the likelihood of long-term
disease control. Complete excision alone can lead to a 5-year disease
free survival rate of 35% [58]. Complete resection followed by loco-
regional radiotherapy results in a 5-year local regional control
ranging from 60 to 77% [59,60]. Long-term predictors of disease free
survival after a local regional recurrence include a disease-free in-
terval greater than 24 months and a complete excision [59].
With modern radiotherapy techniques it is often possible to re-
irradiate with full dose without too many side effects [61]. The first
results of retreatment with stereotactic body radiotherapy (SBRT)
techniques have been published recently, describing promising
local control rates [62].
Concurrent chemoradiation has both preclinical rationale and
clinical efficacy in many solid tumour types. Potential mechanisms
of chemotherapy and radiotherapy interactions include increasing
radiation damage, inhibition of DNA repair processes, enhanced
activity against hypoxic and radioresistant cells, and prevention of
regrowth of tumour after radiation [63]. In patients who have
received prior radiation, chemoradiation can be considered, as the
residual tumour should be considered radioresistant unless com-
bined with a potentiating agent, provided that the patient is judged
a candidate and can tolerate additional radiation therapy. Agents
having shown potential synergy with radiation include platinum
analogs [64], antimetabolites [65e67], and taxanes [68]. Several
novel therapeutics are also being studied in the trial setting in
combination with radiation, including EGFR inhibitors [69], HER-2
inhibitors [70], and PARP inhibitors [71]. Patients who have resid-
ual isolated local-regional recurrence after attempted resection, or
minimal systemic disease, might derive benefit from consideration
of this multi-modality approach.
Hyperthermia has a proven benefit for the treatment of super-
ficial malignancies, acting as a radiosensitizer. Trials evaluating the
role of hyperthermia in combination with radiotherapy in patients
with chest wall recurrences have shown a significant improvement
in complete response rates with the addition of hyperthermia,
especially in previously irradiated patients (e.g. CR: 24%e31% in the
no-hyperthermia arm vs. 57%e68% in the hyperthermia arm)
[72,73]. However, there was no difference in survival between the
two treatment arms. Recent studies have analysed the combination
of radiotherapy, hyperthermia and concurrent chemotherapy in
this patient population [74].
Finally, systemic therapy (both endocrine and chemotherapy)
has been shown to benefit patients after complete resection of a
first locoregional isolated recurrence [75,76]. The CALOR study [76],
a randomized Phase 3 study, allocated 162 patients to either phy-
sician's choice chemotherapy or no chemotherapy. The use of
chemotherapy after surgery resulted in a significant reduction in
systemic recurrence (HR ¼ 0.59; p ¼ 0.046). In the subgroup of
patients with ER-negative tumours, there was also a significant
improvement in survival. This study provides important data in
support of use of systemic chemotherapy after surgical resection of
isolated locoregional recurrence of ER-negative breast cancer.
F. Cardoso et al. / The Breast 23 (2014) 489e502 495Update on ER positive/HER-2 negative ABCGuideline statement LoE Consensus
The preferred 1st line ET for postmenopausal
patients is an aromatase inhibitor or tamoxifen,
depending on type and duration of adjuvant ET.
I A 83.3% (30) Yes
16.6% (6) Abstain
(36 voters)
Fulvestrant HD is also an option. I B 83.3% (30) Yes
16.6% (6) Abstain
(36 voters)
The addition of everolimus to an aromatase
inhibitor is a valid option for some post-
menopausal patients with disease progression
after a non-steroidal aromatase inhibitor, since it
significantly prolongs PFS by a median interval of
5 months. There is a survival prolongation of
similar magnitude (4.4 months) although this
difference is not statistically significant. The
decision to treat must take into account the
relevant toxicities associated with this
combination and should be made on a case by
case basis.
At present, no predictive biomarker exists to
identify those patients who will benefit from this
approach.
I B 100% Yes
(30 voters)
LoE: Available level of evidence; Consensus: Percentage of panel members in
agreement with the statement; ET: endocrine therapy; PFS: progression-free
survival.
Guideline statement LoE Consensus
In the 1st line setting, for HER-2þ MBC previously
treated (in the adjuvant setting) or untreated
with trastuzumab, combinations of
CT þ trastuzumab are superior to combinations
of CT þ lapatinib in terms of PFS and OS.
I A 84.6% (33) Yes
10.2% (4) Abstain
(39 voters)
In 1st line therapy, the combination of
CT þ trastuzumab and pertuzumab is superior to
CT þ trastuzumab, primarily for previously
untreated HER-2þ MBC, making it the preferred
treatment option since it is associated with OS
benefit.
It is currently unknown how this treatment
compares to other anti-HER-2 options such as T-
DM1.
I A 89.7% (35) Yes
10.2% (4) Abstain
(39 voters)
There are currently no data supporting the use of
dual blockade with trastuzumab þ pertuzumab
associated with CT beyond 1st line, after
treatment with trastuzumab þ pertuzumab þ CT
in 1st line (i.e. continuing dual blockade beyond
progression) and therefore this 3 drug regimen





In a HER-2þMBC patient previously untreated with
pertuzumab, it is acceptable to use pertuzumab
beyond 1st line.
II C 43.7% (14) Yes
21.8% (7) Abstain
(32 voters)
After 1st line trastuzumab-based therapy, T-DM1
provides superior efficacy relative to other HER-
2-based therapies in the 2nd line (vs.
lapatinib þ capecitabine) and beyond (vs.
treatment of physician's choice).
T-DM1 should be preferred in patients who have
progressed through at least 1 line of
trastuzumab-based therapy, since it provides an
OS benefit.
I A 89.7% (35) Yes
10.2% (4) Abstain
(39 voters)
All patients with HER-2þ MBC who relapse after
adjuvant anti-HER-2 therapy should be
considered for further anti-HER-2 therapy,
except in the presence of contraindications.
The choice of the anti-HER-2 agent will depend on
country-specific availability, the specific anti-
HER-2 therapy previously administered, and the
relapse free interval.
The optimal sequence of all available anti-HER-2
therapies is currently unknown.
I B 87.5% (35) Yes
12.5% (5) Abstain
(40 voters)
Because patients with HER-2-positive MBC and
brain metastases can live for several years,
consideration of long-term toxicity is important
and less toxic local therapy options (e.g.
stereotactic RT) should be preferred to whole
brain RT, when available and appropriate (e.g. in
the setting of a limited number of brain
metastases).
I C 89.1% (33) Yes
10.8% (4) Abstain
(37 voters)
MBC: metastatic breast cancer; LoE: Available level of evidence; Consensus: Per-
centage of panel members in agreement with the statement; CT: chemotherapy, RT:
radiotherapy; T-DM1: Trastuzumab Emtansine.ABC2 reinforces the ABC1 recommendations for ER-positive/
HER-2-negative advanced breast cancer regarding the preferential
use of endocrine therapy, even in the presence of visceral metas-
tases. Chemotherapy should be reserved for cases of rapidly pro-
gressive disease or proven endocrine-resistance. Most ABC1
recommendations remain unchanged (see Table 2). The two
changes refer to the preferred 1st line endocrine therapy for
postmenopausal women and the use of everolimus.
The preferred 1st line endocrine therapy for postmenopausal
women depends on the type and duration of adjuvant endocrine
therapy. Available data supports the use of an aromatase inhibitor,
tamoxifen or fulvestrant HD (i.e. 500 mg, every 4 weeks)
[31,77e88]. Fulvestrant HD is well tolerated and numerically
associated with a 4.1-month difference in median OS compared
with fulvestrant 250 mg [80]. Only the lower, less efficacious dose,
was compared to aromatase inhibitors and found to have similar
efficacy; so far, no data directly comparing fulvestrant HD with an
aromatase inhibitor exist.
Endocrine resistance is a common and important clinical
problem. It may be primary or secondary (see above ABC defini-
tions). The main identified mechanisms of endocrine resistance are
related to ESR alterations (mutations, amplifications or trans-
locations), and upregulation of alternative pathways, such as the
HER growth factor pathways and the PI3K/Akt/mTOR pathway.
The mTOR inhibitor everolimus when added to exemestane, in
patients progressing on non-steroidal aromatase inhibitor, pro-
vided a significant PFS prolongation of about 5 months [89,90]. The
overall survival data, presented after ABC2, demonstrated a non-
significant 4-month increase in median survival (HR 0.89) [91].
Overall survival prolongation was also observed, in an exploratory
analysis of the randomized phase II TAMRAD study comparing
combination of tamoxifen and everolimus to tamoxifen alone in AI-
resistant patients [92]. These benefits must be weighed against
relevant toxicities associated with this compound, particularly
stomatitis, pneumonitis and hyperglycemia. Decisions on ever-
olimus use must thus be made on a case-by-case basis, after dis-
cussion with a well-informed patient, and administered by
physicians experienced in managing adverse effects of this
compound.Update on Her-2-Positive ABCIn the last two years, several trials in HER-2-positive ABC have
been reported, which led to an update on several ABC1 recom-
mendations regarding this specific subtype.
Evidence from three trials, two in advanced and one in early
breast cancer, support the recommendation that combinations of
chemotherapy with trastuzumab are superior to chemotherapy and
lapatinib.
The MA.31 trial [93] randomly compared taxanes plus trastu-
zumab (weekly paclitaxel or three weekly docetaxel) or the same
taxane plus lapatinib, as first line treatment of 636 HER-2 positive
MBC patients, a substantial percentage of whom had de novo MBC.
With a median follow-up of 13.6 months, the taxane-lapatinib arm
had inferior PFS compared to the taxane-trastuzumab (8.8 vs. 11.4
(continued )
Guideline statement LoE Consensus
Additional choices include gemcitabine, platinum
agents, taxanes, and liposomal anthracyclines.
The decision should be individualized and take into
account different toxicity profiles, previous
exposure, patient preferences, and country
availability.
LoE: Available level of evidence; Consensus: Percentage of panel members in
agreement with the statement; CT: chemotherapy.
Guideline statement LoE Consensus
The true value of the removal of the primary
tumour in patients with de novo stage IV
breast cancer is currently unknown.
However, it can be considered in selected
patients. Of note, some studies suggest that
surgery is only valuable if performed with
the same attention to detail (e.g. attaining
clear margins and addressing disease in the
axilla) as in patients with early stage disease.
II B 100% (29) Yes
0% (0) Abstain
(29 voters)
LoE: Available level of evidence; Consensus: Percentage of panel members in
agreement with the statement.
F. Cardoso et al. / The Breast 23 (2014) 489e502496months). There was no difference in OS and toxicity was signifi-
cantly higher in the lapatinib arm.
The CEREBEL trial [94], compared lapatinib plus capecitabine to
trastuzumab plus capecitabine, as 1st line therapy for HER-2-
positive MBC with no evidence of CNS disease. The primary
endpoint was incidence of CNS metastases as first site of relapse.
With a planned population of 475 patients, the study was termi-
nated at the time of the interim analysis due to a low number of
CNS events (3% and 5% respectively). PFS, a secondary endpoint,
was lower in the lapatinib arm (6.6 vs. 8.0 months).
Additional evidence comes from the adjuvant ALTTO trial,
where the lapatinib alone arm was closed early, due to futility in a
non-inferiority comparison to trastuzumab, and patients offered
cross-over to receive trastuzumab [95].
The CLEOPATRA trial [96,97]; showed superior results, in terms of
PFS (18.5 vs. 12.4 months) and 1-year survival (23.6% vs. 17.2), of the
triplet trastuzumab þ pertuzumab þ docetaxel compared to
trastuzumabþ docetaxel as 1st line therapy. Importantly, themajority
(z90%) of the patients were trastuzumab-naive; if previously treated
with trastuzumab, a 12 months disease-free interval was required.
Therefore, this trial did not address, and therefore cannot support, the
use of this combination in patients with truly trastuzumab-resistant
tumours. There are also no data supporting the use of the dual
blockade with trastuzumab þ pertuzumab with CT beyond 1st line,
after treatment with trastuzumab þ pertuzumab þ CT in 1st line (i.e.
continuing dual blockade beyond progression) and therefore this
regimen should not be given beyond 1st line outside clinical trials.
The panel could not reach a consensus regarding the possible
use of pertuzumab beyond 1st line in patients previously untreated
with this drug (14 votes “yes”, 11 “no”, 7 “abstain”). The only
available data regarding this issue come from a phase II single arm
study [98]. This phase II also showed that pertuzumab does not
work by itself but needs to be combined with trastuzumab.
T-DM1 (Trastuzumab Emtansine) has shown consistent and
substantial benefits in terms of PFS and OS, both in the 2nd line (vs.
lapatinib þ capecitabine, in the EMILIA trial) [99,100]; and beyond
(vs. treatment of physician's choice, in the TH3RESA trial) [101].
These results make T-DM1 the preferred choice for patients with
disease progression after treatment with at least one line of
trastuzumab-based therapy.
There are almost no data regarding the treatment of patients with
HER-2-positive ABC who relapse on or shortly after adjuvant tras-
tuzumab and urgent trials are needed for this poor prognosis pop-
ulation. In the EMILIA trial, the overall survival advantage (hazard
ratio) for T-DM1 vs. lapatinib plus capecitabine in the subset of 118
patients who were randomized in the first-line setting, having
relapsed on or within 6 months of adjuvant trastuzumab, appeared
similar to the effect seen in the overall trial [100].
Several ABC1 recommendations for HER-2-positive ABC remain
unchanged and are listed in Table 2.
Update on HER-2-negative ABCGuideline statement LoE Consensus
Sequential monotherapy is the preferred choice for
MBC. Combination CT should be reserved for
patients with rapid clinical progression, life-
threatening visceral metastases, or need for rapid
symptom and/or disease control.
I A 96% (25) Yes
4% (1) Abstain
(26 voters)
In patients pre-treated (in the adjuvant or
metastatic setting) with an anthracycline and a
taxane, and who do not need combination
chemotherapy, single agent capecitabine,
vinorelbine or eribulin are the preferred choices.
I B 77.1% (27) Yes
20.0% (7) Abstain
(35 voters)Regarding the use of chemotherapy, the main recommendation
remains unchanged and relates to the sequential use of single
agents, with combination chemotherapy reserved for situations of
visceral crisis, rapidly progressive or highly symptomatic disease.
Available literature has been previously reviewed [12] and a recent
Cochrane meta-analysis [102] confirms and provides level 1 evi-
dence for this recommendation.
Although taxanes can be used as first line therapy, they have not
shown superior benefit to anthracyclines in a meta-analysis per-
formed in a mostly taxane-naive, anthracycline-pretreated patient
population [103]. Considerations regarding toxicity and patient
preferences (namely wish to avoid alopecia) should be taken into
consideration in the choice of cytotoxic agent.
Capecitabine has shown consistent results as first and second
line therapy [104e112].
Vinorelbine yielded equal or superior results to both paclitaxel
and docetaxel, when combined with trastuzumab in the HER-2
positive ABC in the HERNATA [113] and TRAVIOTA trials [114].
Eribulin has provided an OS benefit in heavily pretreated pa-
tients (up to 5 lines of treatment) [115] and similar PFS and OS
results to capecitabine after prior treatment with an anthracycline
and taxane [116].Update on surgery of the primary tumour in stage IV at
diagnosisAvailable data regarding the value of removal of the primary
tumour in patients with stage IV at diagnosis were extensively
reviewed and published in one of the ESO ABC Task Force manu-
scripts [13]. All but one study published after this 2010 paper
support the surgical removal of the primary tumour in patients
with stage IV disease, reinforcing the importance of the ongoing
prospective trials evaluating this approach since existing data come
almost exclusively from retrospective studies [117e121,124]. In the
beginning of 2012, the British Columbia large retrospective series
reinforced the importance of treating the primary with the most
favourable survival rates observed in subsets of patients with young
age, good performance status, ER-positive disease, distant disease
limited to one site, bone-only involvement, or fewer than five
Table 2
ABC1 statements [10] with minor update or with no update.
Guideline statement LoE Consensus
The management of ABC is complex and, therefore, involvement of all appropriate specialties in a multidisciplinary team (including
but not restricted to medical, radiation, surgical oncologists, imaging experts, pathologists, gynaecologists, psycho-oncologists,






From the time of diagnosis of ABC, patients should be offered appropriate psychosocial care, supportive care, and symptom-related






Following a thorough assessment and confirmation of MBC, the potential treatment goals of care should be discussed. Patients
should be told that MBC is incurable but treatable, and that some patients can live with MBC for extended periods of time (many
years in some circumstances).
This conversation should be conducted in accessible language, respecting patient privacy and cultural differences, and whenever






Patients (and their families, caregivers or support network, if the patient agrees) should be invited to participate in the decision-
making process at all times. When possible, patients should be encouraged to be accompanied by persons who can support them






There are few proven standards of care in ABC management. After appropriate informed consent, inclusion of patients in well-







The medical community is aware of the problems raised by the cost of ABC treatment. Balanced decisions should be made in all







Minimal staging workup for MBC includes a history and physical examination, haematology and biochemistry tests, and imaging of
chest, abdomen and bone.
2 C 67% (20) Yes
3% (1) Abstain
(30 voters)
Brain imaging should not be routinely performed in asymptomatic patients. This approach is applicable to all patients with MBC






The clinical value of tumour markers is not well established for diagnosis or follow-up after adjuvant therapy, but their use is
reasonable (if elevated) as an aid to evaluate response to treatment, particularly in patients with non-measurable metastatic
disease. A change in tumour markers alone should not be used to initiate a change in treatment.
2 C 89% (24) Yes
4% (1) Abstain
(27 voters)
Evaluation of response to therapy should generally occur every 2e4 months for ET or after 2 to 4 cycles for CT, depending on the
dynamics of the disease, the location and extent of metastatic involvement, and type of treatment.
Imaging of a target lesion may be sufficient in many patients. In certain patients, such as those with indolent disease, less frequent
monitoring is acceptable.
Additional testing should be performed in a timely manner, irrespective of the planned intervals, if PD is suspected or new






A biopsy (preferably providing histology) of a metastatic lesion should be performed, if easily accessible, to confirm diagnosis
particularly when metastasis is diagnosed for the first time.
1 C* 96% (27) Yes
0% (0) Abstain
(28 voters)
Biological markers (especially HR and HER-2) should be reassessed at least once in the metastatic setting, if clinically feasible. 2 C 90% (26) Yes
7% (2) Abstain
(29 voters)
If the results of tumour biology in the metastatic lesion differ from the primary tumour, it is currently unknownwhich result should
be used for treatment-decision making. Since a clinical trial addressing this issue is difficult to undertake, we recommend








Treatment choice should take into account at least these factors: HR and HER-2 status, previous therapies and toxicities, disease-free
interval, tumour burden (defined as number and site of metastases), biological age, performance status, co-morbidities (including
organ dysfunctions), menopausal status (for ET), need for a rapid disease/symptom control, socio-economic and psychological






A small but very important subset of patients with MBC, for example those with oligo-metastatic disease, can achieve complete
remission and a long survival. A multimodal approach should be considered for these selected patients.






ER þ/HER-2 negative ABC
Endocrine therapy (ET) is the preferred option for hormone receptor positive disease, even in the presence of visceral disease, unless
there is concern or proof of endocrine resistance, or there is disease needing a fast response.
I A 100% (29) Yes
0% (0) Abstain
(29 voters)
For pre-menopausal women, ovarian suppression/ablation combined with additional endocrine therapy is the first choice. I A 97% (29) Yes
0% (0) Abstain
(30 voters)
The additional endocrine agent should be tamoxifen unless tamoxifen resistance is proven.
An aromatase inhibitor is also a viable option, but absolutely mandates the use of ovarian suppression/ablation.
Fulvestrant has not been adequately studied in premenopausal women.
I B 97% (29) Yes
0% (0) Abstain
(30 voters)
Optimal post-aromatase inhibitor treatment is uncertain. Available options include, but are not limited to, tamoxifen, another
aromatase inhibitor (with a different mechanism of action), fulvestrant HD, megestrol acetate and everolimus þ aromatase
inhibitor.
I A 97% (30) Yes
3% (1) Abstain
(31 voters)
(continued on next page)
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Table 2 (continued )
Guideline statement LoE Consensus
Endocrine treatment after CT (maintenance ET) to maintain benefit is a reasonable option, although this approach has not been
assessed in randomized trials.
I C 88% (28) Yes
9% (3) Abstain
(32 voters)




Anti-HER-2 therapy should be offered early to all patients with HER-2þMBC, except in the presence of contra-indications to the use
of such therapy.
I A 91% (30) Yes
3% (1) Abstain
(33 voters)
For patients with ERþ/HER-2þ MBC for whom ET was chosen over CT, anti-HER-2 therapy þ ET should be considered with the
initiation of endocrine therapy (provided that further anti-HER-2 therapy is available) since anti-HER-2 therapy (either
trastuzumab or lapatinib) in combinationwith ET has shown substantial PFS benefit (i.e. “timewithout CT”) compared to ET alone.
The addition of anti-HER-2 therapy in this setting has not led to a survival benefit.
I A 90% (27) Yes
10% (3) Abstain
(30 voters)
Patients whose tumours progress on an anti-HER-2 therapy combined with a cytotoxic or endocrine agent should be offered
additional anti-HER-2 therapy with subsequent treatment since it is beneficial to continue suppression of the HER-2 pathway.
The optimal duration of anti-HER-2 therapy for MBC (i.e. when to stop these agents) is currently unknown.
I B 97% (29) Yes
0% (0) Abstain
(30 voters)
Patients who have received any type of (neo)adjuvant anti-HER-2 therapy should not be excluded from clinical trials for HER-2þ
MBC.
I B 100% (23) Yes
0% (0) Abstain
(27 voters)
In case of progression on trastuzumab, the combination of trastuzumab þ lapatinib is also a reasonable treatment option in the
course of the disease.
I B 83% (24) Yes
10% (3) Abstain
(29 voters)
Chemotherapy and biological therapy
In the absence of medical contraindications or patient concerns, anthracycline or taxane based regimens, preferably as single agents,
would usually be considered as first line CT for HER-2 negative MBC, in those patients who have not received these regimens as
adjuvant treatment and for whom chemotherapy is appropriate. Other options are, however, available and effective, such as
capecitabine and vinorelbine, particularly if avoiding alopecia is a priority for the patient.
I A 71% (17) Yes
4% (1) Abstain
(24 voters)
In patients with taxane-naive and anthracycline-resistant MBC or with anthracycline cumulative dose or toxicity (i.e. cardiac) who
are being considered for further CT, taxane-based therapy, preferably as single agents, would usually be considered as treatment
of choice. Other options are, however, available and effective, such as capecitabine and vinorelbine, particularly if avoiding
alopecia is a priority for the patient.
I A 59% (14) Yes
8% (2) Abstain
(24 voters)
If given in the adjuvant setting, a taxane can be re-used in the metastatic setting, particularly if there has been at least one year of
disease-free survival.
I A 92% (22) Yes
8% (2) Abstain
(24 voters)





Usually each regimen (except anthracyclines) should be given until progression of disease or unacceptable toxicity.
What is considered unacceptable should be defined together with the patient.
I B 72% (21) Yes
7% (2) Abstain
(29 voters)
Bevacizumab combined with a chemotherapy as 1st or 2nd line therapy for MBC provides only a moderate benefit in PFS and no
benefit in OS. The absence of known predictive factors for bevacizumab efficacy renders recommendations on its use difficult.
Bevacizumab can only therefore be considered as an option in selected cases in these settings and is not recommended after 1st/
2nd line.
I A 74% (17) Yes
17% (4) Abstain
(23 voters)
Specific sites of metastases: bone and brain
A bone modifying agent (bisphosphonate or denosumab) should be routinely used in combination with other systemic therapy in
patients with MBC and bone metastases.
I A 96% (26) Yes
4% (1) Abstain
(27 voters)
Radiological assessments are required in patients with persistent and localized pain due to bone metastases to determine whether
there are impending or actual pathological fractures. If a fracture of a long bone is likely or has occurred, an orthopaedic
assessment is required as the treatment of choice may be surgical stabilization, which is generally followed by RT. In the absence
of a clear fracture risk, RT is the treatment of choice.
I A 96% (23) Yes
4% (1) Abstain
(24 voters)
Neurological symptoms and signs which suggest the possibility of spinal cord compression must be investigated as a matter of
urgency. This requires a full radiological assessment of potentially affected area as well as adjacent areas of the spine. MRI is the
method of choice. An emergency surgical opinion (neurosurgical or orthopaedic) may be required for surgical decompression. If
no decompression/stabilization is feasible, emergency radiotherapy is the treatment of choice and vertebroplasty is also an
option.
I B 100% (24) Yes
0% (0) Abstain
(24 voters)
Patients with a single or small number of potentially resectable brain metastases should be treated with surgery or radiosurgery.
Radiosurgery is an option for some unresectable brain metastases.
I B 92% (22) Yes
4% (1) Abstain
(24 voters)
If surgery/radiosurgery is performed it may be followed by whole brain radiotherapy but this should be discussed in detail with the
patient, balancing the longer duration of intracranial disease control against the risk of neurocognitive effects.
I B 72% (18) Yes
16% (4) Abstain
(25 voters)
Supportive and palliative care
Supportive care allowing safer and more tolerable delivery of appropriate treatments should always be part of the treatment plan. I A 100% (26) Yes
0% (0) Abstain
(26 voters)
Early introduction of expert palliative care, including effective control of pain and other symptoms, should be a priority. I A 100% (26) Yes
0% (0) Abstain
(26 voters)
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Guideline statement LoE Consensus
Access to effective pain treatment (including morphine, which is inexpensive) is necessary for all patients in need of pain relief. I A 100% (27) Yes
0% (0) Abstain
(27 voters)
Optimally, discussions about patient preferences at the end of life should begin early in the course of metastatic disease. However,
when active treatment no longer is able to control widespread and life-threatening disease, and the toxicities of remaining
options outweigh benefits, physicians and other members of the healthcare team should initiate discussions with the patient (and






Metastatic male breast cancer
For ER þMale MBC, which represents the majority of cases, ET is the preferred option, unless there is concern or proof of endocrine











*LoE changed since ABC1 from 2 C to 1 C based on new published data [128e130].
F. Cardoso et al. / The Breast 23 (2014) 489e502 499metastatic lesions [122]. A meta-analysis of 15 publications also
published in 2012 reinforced the idea that surgery of the primary
tumour appeared to be an independent factor for improved survival
in the multivariate analyses from the individual studies, with an HR
of 0.69 (p < 0.00001) [123].
Since 2011 several randomized trials have started accrual
comparing loco-regional treatment of primary vs. no treatment in
stage IV patients at presentation [124,125].
In 2013, very early data from 2 prospectively randomized trials
presented at San Antonio Breast Cancer Symposium could not
confirm the previous conclusions. In these two studies, only a
limited subgroup of patients with solitary bone metastases seemed
to profit from surgery, while patients with multiple visceral me-
tastases showed a worse prognosis with initial surgery. However,
these trials were small, had short follow-up time and included all-
comers [126,127].
More studies and better patient selection are necessary to
resolve this question, and several other prospective randomized
trials are ongoing. Until these results are available, ABC2 retains the
ABC1 recommendation, which considers that surgery of the pri-
mary should not be offered as a routine practice but can be dis-
cussed on a case-by-case basis and offered to selected patients.Conclusions
Advances in survival outcomes for ABC, particularly for MBC,
have been frustratingly slow. MBC remains a virtually incurable
disease and LABC patients generally have a poor prognosis with a
high risk of distant recurrence.
In the last few years, a deeper focus on this historically
neglected patient population has occurred, with new and better
designed clinical trials, a dedicated conference and the develop-
ment of international consensus guidelines. Patient surveys have
shown a slight improvement in patient satisfaction about the
several steps of their care but emphasize that much remains to be
done. Implementation of guidelines is very heterogeneous between
countries but also within countries, according to the environment
where the patient is treated and cost of treatment.
The complexity of this disease, the multiple factors that must be
taken into account, the lack of high-level evidence for several
clinical situations, and new highly specialized techniques available
for local management of specific sites of metastases, all constitute
strong reasons for the treatment of these patients by a specialized
multidisciplinary team, rather than management by an isolated
oncologist regardless of his/her skills or experience.
Our plea for a strong commitment of all involved parties
(academia, pharmaceutical industry, independent funding sources,advocacy groups) to develop well designed, high quality multidis-
ciplinary (involving other issues than drug-development) trials for
ABC remains of critical importance. Many questions are still
unanswered, related to management strategies, optimal drug use,
and individualized treatment (based on predictive markers and
eventually new technologies aiming at better characterization of
the individual tumour).
Research and education are the two pillars for advances in
oncology today. Research is indispensible for improving the man-
agement and outcome of patients with cancer, now and in the
future. Education, including implementation of carefully developed
high quality guidelines such as the current ABC International
Consensus Guidelines, allows the appropriate application of cur-
rent knowledge to patient care, which will substantially improve
the long-term outcomes of current ABC patients worldwide.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.breast.2014.08.009.
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